

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. TSRI 481.2	SERIAL NO. 09/194,552
		APPLICANT Brooks, et al.	
		FILING DATE March 23, 1999	GROUP 1642
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			

JUN 11 2001
U.S. DEPARTMENT OF COMMERCE
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
amh	95/14714	6/1/95	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

amh	10	Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996, <i>Nature Med.</i> , 2(5):529-533.
amh	11	Brooks, et al., Integrin $\alpha v\beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994, <i>Cell</i> , 79:1157-1164.
amh	12	Clark, et al., Transient functional expression of $\alpha v\beta 3$ on vascular cells during wound repair, 1996, <i>Am. J Pathol.</i> , 148:1407-1421.
amh	13	Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992, <i>J. Cell. Physiol.</i> , 153:437-449.
amh	14	Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992, <i>Seminars in Cancer Biology</i> , 3:57-63.
amh	15	Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993, <i>Intl. J. Cancer</i> , 55:1023-1028.
amh	16	Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992, <i>Cell</i> , 69:11-25.
amh	17	Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha v\beta 3$, $\alpha v\beta 5$ and $\alpha v\beta 6$, 1994, <i>Cancer Res.</i> , 54:2102-2107.

EXAMINER <i>amh/farris</i>	DATE CONSIDERED <i>October 9, 2001</i>
-------------------------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. TSRI 481.2	SERIAL NO. 09/194,552
		APPLICANT Brooks, et al.	
INFORMATION DISCLOSURE STATEMENT BY ATTORNEY OR TRADEMARK OFFICE		FILING DATE March 23, 1999	GROUP 1642

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)


amh	18	Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987, <i>J. Biol. Chem.</i> , 262:17294-17296.
↓	19	Folkman, et al., Angiogenesis, 1992, <i>J. Biol. Chem.</i> , 267:10931-10934.
amh	20	Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994, <i>Intl. J. Cancer</i> , 57:920-925.
amh	21	Drake, et al., A antagonist of integrin $\alpha v \beta 3$ prevent maturation of blood vessels during embryonic neovascularization, 1995, <i>J. Cell Sci.</i> , 108:2655-2661.
amh	22	Folkman, et al., Inhibition of angiogenesis, 1992, <i>Cancer Bio.</i> , 3:89-96.
amh	23	Aumailley, et al., Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin-fragment P1, 1991, <i>FEBS</i> , 291(1):50-54.
↓	24	Choi, et al., Inhibition of neointimal hyperplasia by blocking $\alpha v \beta 3$ integrin with a small peptide antagonist GopenGRGDSPCA, 1994, <i>J. Vasc. Surg.</i> , 19:125-134.
	25	
	26	

EXAMINER	DATE CONSIDERED
amh	October 3, 2001


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM 10-1449 U.S. DEPARTMENT OF COMMERCE <small>PATENT AND TRADEMARK OFFICE</small> <small>JUN 1 1 2008</small> <small>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</small>					ATTY DOCKET NO. TSR 481.0	SERIAL NO. 08/514,799	
					APPLICANT Brooks, et al.	FILING DATE 8/14/95	GROUP <i>1692</i> unknown
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>Amstarris</i>		4,517,686	5/21/85	Ruoslahti			
		4,578,079	3/25/86	Ruoslahti			
		4,589,881	5/20/86	Pierschbacher			
		4,614,517	9/30/86	Ruoslahti			
		4,661,111	4/28/87	Ruoslahti			
		4,683,291	7/28/87	Zimmerman			
FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)							
<i>Amstarris</i>	1	Brooks, et al., "Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis", <u>J. Cell Biology</u> , 122: 1351-1359 (1993)					
	2	Brooks, et al., Requirement of Vascular Integrin Alpha v Beta 3 for Angiogenesis in <u>Science</u> , 264: 569-571 (1994)					
	3	Brown, et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer", <u>Human Path.</u> , 26:86 (1995)					
	4	Cheng, et al., "Human Microvascular Endothelial Cells Express Integrin-Related Complexes that Mediate Adhesion to the Extracellular Matrix", <u>J. Cell Physiol.</u> , 139: 275-286 (1989)					
<i>V</i>	5	Cheresh, David A., "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and					
EXAMINER	<i>Amstarris</i>			DATE CONSIDERED	<i>October 3, 2001</i>		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 				ATTY DOCKET NO. TSR 481.0	SERIAL NO. 08/514,799		
				APPLICANT Brooks, et al.			
				FILING DATE 8/14/95	GROUP unknown 1642		
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>Amh</i>		4,792,525	12/20/88	Ruoslahti			
<i>J</i>		4,879,237	11/7/89	Ruoslahti			
		4,988,621	1/29/91	Ruoslahti			
		5,041,380	8/20/91	Ruoslahti			
<i>V</i>		5,061,693	10/29/91	Nutt			
FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)							
<i>Amh</i>		von Willebrand factor", Proc. Natl. Acad. Sci., USA, 84: 6471-6475 (1987)					
<i>J</i>	6	Davis, et al., "Identification of a Role of the Vitronectin Receptor and Protein Kinase C in the Induction of Endothelial Cell Vascular Formation", J. Cellular Biochemistry, 51: 206-218 (1993)					
	7	Horton, Michael, "Current Status Review Vitronectin receptor: tissue specific expression or adaptation to culture?", Int. J. Exp. Path., 71: 741-759 (1990)					
	8	Janat, et al., "Regulation of Vascular Smooth Muscle Cell Integrin Expression by Transforming Growth Factor beta 1 by Platelet-Derived Growth Factor-BB", J. Cellular Physiol., 151: 588-595 (1992)					
	9	Nicosia, et al., "Rapid Communication: Inhibition of Angiogenesis in vitro by Arg-Gly-Asp-Containing Synthetic Peptide", Am. J. Path., 138: 829-833 (1991)					
EXAMINER <i>Amh</i>		DATE CONSIDERED <i>October 9, 2001</i>					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.




FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. TSR 481.0	SERIAL NO. 08/514,799		
				APPLICANT Brooks, et al.			
				FILING DATE 8/14/95	GROUP <u>unknown</u> 1642		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT							
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)							
<i>amh</i>	10	Pasqualini, et al., "A study of the structure, function and distribution of beta 5 integrins using novel anti-beta 5 monoclonal antibodies", J. Cell Science, 105: 101-111 (1993)					
	11	Pfaff, et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by aIIbB3, aVB3, and a5B1 Integrins", J. Biol. Chem., 269: 20233-20238 (1994)					
	12	Wayner, et al., "Integrins avB3 and avB5 Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface", Journ. of Cell Biol., 113: 919-929 (1991)					
EXAMINER	<i>Am Harris</i>			DATE CONSIDERED	<i>October 3, 2001</i>		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.
TSRI 481.2SERIAL NO.
09/194,552

APPLICANT

Brooks, et al.

FILING DATE
March 23, 1999GROUP
1642INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
Amh	AA	5,575,815	11/19/96	Slepian, et al.	—	—	
✓	AB	5,849,692	12/15/98	Jonczyk, et al.	—	—	
Amh	AC	5,968,902	10/19/99	Scarborough, et al.	—	—	
Amh	AD	5,981,478	11/9/99	Ruoslahti, et al.	—	—	
Amh	AE	5,866,540	2/2/99	Jonczyk, et al.	—	—	
Amh	AF	5,135,919	8/4/92	Folkman, et al.	—	—	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
Amh	AC	95/28426	10/26/95	PCT	—	—	
✓	AH	97/14716	4/24/97	PCT	—	—	
Amh	AJ	0 770 622 A	5/2/97	EPO	—	—	entire document in German
Amh	AS	89/06536	7/27/89	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

Amh	1	Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994, <i>Circulation</i> , 90(5):2203-2205.
✓	2	Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996, <i>Eur. J. Cancer</i> , 32A(1):152-159.
Amh	3	Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, <i>Biochem J.</i> , 300:729-736.
✓	4	Friedlander, et al., Definition of two angiogenic pathways by distinct $\alpha\beta$ integrins, 1995, <i>Science</i> , 270:1500-1502.
Amh	5	Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins $\alpha\text{IIb}\beta 3$, $\alpha\text{v}\beta 3$ and $\alpha 5\beta 1$ and in cell adhesion inhibition, 1994, <i>Cell Adhes. Commun.</i> , 2(6):491-501.
✓	6	Smith, et al., Interaction of integrins $\alpha\text{v}\beta 3$ and glycoprotein IIb-IIIa with fibrinogen, 1990, <i>J. Biol. Chem.</i> , 265:12267-12271.
Amh	7	Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1991, 4(2):99-106.
✓	8	Ossowski, et al., Experimental model for quantitative study of metastasis, 1980, <i>Cancer Res.</i> , 40:2300-2309.
✓	9	Klein, et al., Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells, 1993, <i>Mol. Biol. Cell</i> , 4:973-982.
EXAMINER	DATE CONSIDERED	
Amh	October 9, 2001	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.